TAVR is performed with the support of self-expanding valves, SEVs.
An international medical study has brought new findings and related findings are of important reference value for disease prevention. A rapidly growing alternative approach has been developed to the thromboembolic total arterial thrombosis (TS) pathway, particularly in patients with severe acute venous thrombosis (AAWSS) with hostile venous thrombosis (IL) pathways. The main objective of this study is to explore the clinical outcomes of TS-TAVR and TF-TAVR in patients with severe venous thrombosis (AAWSS).
Specifically, this study will evaluate the following clinical indicators: (1) survival rate; (2) incidence of complications; In addition, the study will evaluate the following laboratory examinations: 1) blood flow variation examination; 2) blood clotting function examination; 3) urine analysis. Through these studies, the study aims to provide scientific evidence and references for the clinical findings of TS-TAVR and TF-TAVR in patients with severe AAWSS. We conducted a retrospective analysis of continuous TS- or TF-TAVR patients in our hospital between August 2017 and May 2025, with a total of 817 patients receiving TF-TAVR and 75 receiving TS-TAVR.
The 30-day mortality rate is significantly higher than the analysis results of the unadjusted data (HR 2. 64, 95% CI: 1. 00-6.
97, p<0. 05); in addition, the 30-day mortality rate is significantly higher in high-risk groups (such as coronary heart disease) than in the unadjusted data (HR 2. 44, 95% CI: 1.
19-5. 01, p<0. 01).
Overall, TS-TAVR appears likely to be a viable intervention method when TF-TAVR is not feasible. Adjusted data did not find statistical significance associated with early mortality. However, a significant association of visiting sites with stroke and major bleeding incidence is significant, and these findings may be attributed to the possibility of differences in the incidence of stroke and major bleeding in the treatment group based on a mid-to-low baseline risk based on a mid-to-low baseline.
It should be pointed out that the above content is based on international public research findings and is for reference in HealthCop and does not constitute clinical advice. If you have any health questions, please consult professional medical personnel.
